{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:04:48Z","timestamp":1790165088647,"version":"4.1.0"},"reference-count":106,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>\n                    KarXT (marketed as Cobenfy\u2122), a fixed-dose combination of xanomeline and trospium chloride, represents the first new mechanism of action of an antipsychotic used for adult schizophrenia approved by the US Food and Drug Administration (FDA) in over 30 years. While mainstream drugs (e.g. haloperidol, chlorpromazine, risperidone, olanzapine, quetiapine, aripiprazole) mainly antagonize dopamine D\n                    <jats:sub>2<\/jats:sub>\n                    or serotonin 5-HT\n                    <jats:sub>2A<\/jats:sub>\n                    receptors, KarXT acts through transient activation of muscarinic M1 and M4 receptors. M4 stimulation influences the functioning of mesolimbic dopaminergic pathways, providing an indirect means of regulating dopamine release that bypasses D2 blockade. Trospium, a peripherally acting muscarinic receptor antagonist, was used to reduce anticholinergic adverse effects (AEs). It does not cross the blood\u2013brain barrier and therefore minimizes central adverse events. In a series of randomized placebo-controlled phase 2 and 3 studies, the KarXT significantly and clinically meaningfully reduced Positive and Negative Syndrome Scale (PANSS) total scores. The effect sizes were moderate to large with few extrapyramidal symptoms (EPS), minimal metabolic disturbances and no significant prolactin level increases. In this narrative review, we discuss in detail the pharmacological mechanism, basis of preclinical development, and clinical outcomes of KarXT. We also contextualize this drug within the development of a new wave of non-D2 antipsychotics, highlighting cholinergic dysfunction as one important mechanistic pathway within the broader multidimensional neurobiology of schizophrenia.\n                  <\/jats:p>","DOI":"10.3389\/fpsyt.2026.1828831","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:42:05Z","timestamp":1790163725000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond dopamine: KarXT and emerging mechanism-based therapies in schizophrenia"],"prefix":"10.3389","volume":"17","author":[{"given":"Izabela","family":"\u017buraw","sequence":"first","affiliation":[{"name":"Students Science Club \u201cNEURON\u201c, Faculty of Medicine, Collegium Medicum, University of Rzesz\u00f3w","place":["Rzesz\u00f3w, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystian","family":"Urba\u0144ski","sequence":"additional","affiliation":[{"name":"Students Science Club \u201cNEURON\u201c, Faculty of Medicine, Collegium Medicum, University of Rzesz\u00f3w","place":["Rzesz\u00f3w, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patryk","family":"Kogut","sequence":"additional","affiliation":[{"name":"Department of Human Physiology, Faculty of Medicine, Collegium Medicum, University of Rzesz\u00f3w","place":["Rzesz\u00f3w, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrycja","family":"Pa\u0144czyszyn-Trzewik","sequence":"additional","affiliation":[{"name":"Department of Human Physiology, Faculty of Medicine, Collegium Medicum, University of Rzesz\u00f3w","place":["Rzesz\u00f3w, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Sowa-Ku\u0107ma","sequence":"additional","affiliation":[{"name":"Department of Human Physiology, Faculty of Medicine, Collegium Medicum, University of Rzesz\u00f3w","place":["Rzesz\u00f3w, Poland"]},{"name":"Centre for Innovative Research in Medical and Natural Sciences, Faculty of Medicine, Collegium Medicum, University of Rzesz\u00f3w","place":["Rzesz\u00f3w, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"B1","unstructured":"Schizophrenia\n          \n          \n          \n          2025"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-021-01161-7","article-title":"Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies","volume":"27","author":"Solmi","year":"2022","journal-title":"Mol Psychiatry"},{"key":"B3","article-title":"Suicide in schizophrenia","volume":"7","author":"Perenyi","year":"2005","journal-title":"Neuropsychopharmacol Hung"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1177\/0269881120936919","article-title":"The neurobiology of suicide in psychosis: a systematic review","volume":"34","author":"Girgis","year":"2020","journal-title":"J Psychopharmacol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-023-01949-9","article-title":"Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment","volume":"28","author":"McCutcheon","year":"2023","journal-title":"Mol Psychiatry"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60122060","article-title":"Exploring cognitive deficits and neuromodulation in schizophrenia: a narrative review","volume":"60","author":"Hung","year":"2024","journal-title":"Med (Kaunas)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.12740\/PP\/132953","article-title":"Etiopathogenesis of schizophrenia \u2013 the state of the art for 2021","volume":"55","author":"Rybakowski","year":"2021","journal-title":"Psychiatr Pol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/wps.20693","article-title":"Dopamine and glutamate in schizophrenia: biology, symptoms and treatment","volume":"19","author":"McCutcheon","year":"2020","journal-title":"World Psychiatry"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-023-01991-7","article-title":"Variability and magnitude of brain glutamate levels in schizophrenia: a meta and mega-analysis","volume":"28","author":"Merritt","year":"2023","journal-title":"Mol Psychiatry"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2022.105010","article-title":"Neurofunctional correlates of glutamate and GABA imbalance in psychosis: a systematic review","volume":"144","author":"Zahid","year":"2023","journal-title":"Neurosci Biobehav Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-3-15","article-title":"Chlorpromazine for schizophrenia: a Cochrane systematic review of 50 years of randomised controlled trials","volume":"3","author":"Adams","year":"2005","journal-title":"BMC Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01689-8","article-title":"Real-world data on the adverse metabolic effects of second-generation antipsychotics and their potential determinants in adult patients: a systematic review of population-based studies","volume":"38","author":"Bernardo","year":"2021","journal-title":"Adv Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/wps.21036","article-title":"Metabolic side effects in persons with schizophrenia during mid- to long-term treatment with antipsychotics: a network meta-analysis of randomized controlled trials","volume":"22","author":"Burschinski","year":"2023","journal-title":"World Psychiatry"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1257460","article-title":"Second-generation antipsychotics and metabolic syndrome: a role for mitochondria","volume":"14","author":"Mortimer","year":"2023","journal-title":"Front Psychiatry"},{"key":"B15","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41398-021-01613-2","article-title":"Efficacy and safety of clozapine in psychotic disorders\u2014a systematic quantitative meta-review","volume":"11","author":"Wagner","year":"2021","journal-title":"Transl Psychiatry"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S225643","article-title":"Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment","volume":"16","author":"Correll","year":"2020","journal-title":"Neuropsychiatr Dis Treat"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30060-0","article-title":"Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial","volume":"389","author":"N\u00e9meth","year":"2017","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12991-020-00305-3","article-title":"Treating schizophrenia with cariprazine: from clinical research to clinical practice. Real world experiences and recommendations from an international panel","volume":"19","author":"Fagiolini","year":"2020","journal-title":"Ann Gen Psychiatry"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2019.4379","article-title":"Efficacy and safety of lumateperone for treatment of schizophrenia: a randomized clinical trial","volume":"77","author":"Correll","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2016.16050503","article-title":"Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group consensus guidelines on diagnosis and terminology","volume":"174","author":"Howes","year":"2017","journal-title":"Am J Psychiatry"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41537-024-00525-6","article-title":"Efficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week randomized, double-blind, placebo-controlled EMERGENT trials","volume":"10","author":"Kaul","year":"2024","journal-title":"Schizophrenia"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.102250","article-title":"Xanomeline-trospium chloride as a new paradigm in the treatment of schizophrenia through muscarinic modulation: a renewed hope in psychiatric care","volume":"18","author":"Raza","year":"2026","journal-title":"Cureus"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2017015","article-title":"Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia","volume":"384","author":"Brannan","year":"2021","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02190-6","article-title":"Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomized, double-blind, placebo-controlled, flexible-dose phase 3 trial","volume":"403","author":"Kaul","year":"2024","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2024.0785","article-title":"Efficacy and safety of xanomeline-trospium chloride in schizophrenia: a randomized clinical trial","volume":"81","author":"Kaul","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"B27","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/s41398-022-02254-9","article-title":"Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study","volume":"12","author":"Sauder","year":"2022","journal-title":"Transl Psychiatry"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/ph17050610","article-title":"The new horizon of antipsychotics beyond the classic dopaminergic hypothesis\u2014the case of the xanomeline-trospium combination: a systematic review","volume":"17","author":"Vasiliu","year":"2024","journal-title":"Pharm (Basel)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2020.112989","article-title":"Muscarinic M1 and M4 receptors: hypothesis driven drug development for schizophrenia","volume":"288","author":"Dean","year":"2020","journal-title":"Psychiatry Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107510","article-title":"IUPHAR review on muscarinic M1 and M4 receptors as drug treatment targets relevant to the molecular pathology of schizophrenia","volume":"210","author":"Dean","year":"2024","journal-title":"Pharmacol Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2008.12.002","article-title":"Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders","volume":"30","author":"Conn","year":"2009","journal-title":"Trends Pharmacol Sci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2016.08.017","article-title":"Antipsychotic-like effects of M4 positive allosteric modulators are mediated by CB2 receptor-dependent inhibition of dopamine release","volume":"91","author":"Foster","year":"2016","journal-title":"Neuron"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106711","article-title":"Central nervous system interaction and crosstalk between nAChRs and other ionotropic and metabotropic neurotransmitter receptors","volume":"190","author":"Bono","year":"2023","journal-title":"Pharmacol Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(00)01017-9","article-title":"The muscarinic agonist xanomeline increases monoamine release and immediate early gene expression in the rat prefrontal cortex","volume":"49","author":"Perry","year":"2001","journal-title":"Biol Psychiatry"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1996.tb34418.x","article-title":"M1 agonists for the treatment of Alzheimer's disease. Novel properties and clinical update","volume":"777","author":"Fisher","year":"1996","journal-title":"Ann N Y Acad Sci"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1997.00550160091022","article-title":"Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease","volume":"54","author":"Bodick","year":"1997","journal-title":"Arch Neurol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2008.06091591","article-title":"Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia","volume":"165","author":"Shekhar","year":"2008","journal-title":"Am J Psychiatry"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02126-0","article-title":"Xanomeline\/trospium chloride: first approval","volume":"85","author":"Syed","year":"2025","journal-title":"Drugs"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2023.1340725","article-title":"Regulation of Src family kinases by muscarinic acetylcholine receptors in heterologous cells and neurons","volume":"16","author":"Mao","year":"2024","journal-title":"Front Mol Neurosci"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2024.117728","article-title":"M1\/M4 receptors as potential therapeutic treatments for schizophrenia: a comprehensive study","volume":"105","author":"Fu","year":"2024","journal-title":"Bioorg Med Chem"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-025-03023-y","article-title":"Cholinergic system in schizophrenia: a systematic review and meta-analysis","volume":"30","author":"Saint-Georges","year":"2025","journal-title":"Mol Psychiatry"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23082087","article-title":"Current concepts and treatments of schizophrenia","volume":"23","author":"St\u0119pnicki","year":"2018","journal-title":"Molecules"},{"key":"B43","article-title":"Schizophrenia: overview and treatment options","volume":"39","author":"Patel","year":"2014","journal-title":"Pharm Ther"},{"key":"B44","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/PROM.S42735","article-title":"Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies","volume":"5","author":"Haddad","year":"2014","journal-title":"Patient Relat Outcome Meas"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1017\/S2045796021000494","article-title":"Cardiovascular and metabolic risk of antipsychotics in children and young adults: a multinational self-controlled case series study","volume":"30","author":"Man","year":"2021","journal-title":"Epidemiol Psychiatr Sci"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1097\/YCO.0b013e32833f46c9","article-title":"Cardiovascular aspects of antipsychotics","volume":"23","author":"Raedler","year":"2010","journal-title":"Curr Opin Psychiatry"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241512374","article-title":"Insights into the mechanism of action of antipsychotic drugs derived from animal models: standard of care versus novel targets","volume":"24","author":"Grace","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2024.30.6.629","article-title":"Xanomeline-trospium in schizophrenia: a detailed review and comparison with the Institute for Clinical and Economic Review's analysis","volume":"30","author":"Sutera","year":"2024","journal-title":"J Manag Care Spec Pharm"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3458.2003.tb00247.x","article-title":"Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists","volume":"9","author":"Mirza","year":"2003","journal-title":"CNS Drug Rev"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.2c00592","article-title":"M1\/M4-preferring muscarinic cholinergic receptor agonist xanomeline reverses wake and arousal deficits in nonpathologically aged mice","volume":"14","author":"Russell","year":"2023","journal-title":"ACS Chem Neurosci"},{"key":"B51","article-title":"Cobenfy (Xanomeline and Trospium) [Prescribing Information]","year":"2024"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300151","article-title":"The muscarinic M1\/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys","volume":"28","author":"Andersen","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(99)00138-3","article-title":"Xanomeline, an M1\/M4 preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice","volume":"42","author":"Shannon","year":"2000","journal-title":"Schizophr Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145710001549","article-title":"The M1\/M4 preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia","volume":"14","author":"Barak","year":"2011","journal-title":"Int J Neuropsychopharmacol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-024-01377-9","article-title":"Current findings and potential mechanisms of KarXT (xanomeline-trospium) in schizophrenia treatment","volume":"44","author":"Azargoonjahromi","year":"2024","journal-title":"Clin Drug Investig"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464210-00005","article-title":"Trospium chloride in the management of overactive bladder","volume":"64","author":"Rovner","year":"2004","journal-title":"Drugs"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03275-8","article-title":"Trospium chloride in the treatment of overactive bladder syndrome and detrusor overactivity","volume":"42","author":"Truzzi","year":"2025","journal-title":"Adv Ther"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544070-00003","article-title":"Clinical pharmacokinetics of trospium chloride","volume":"44","author":"Doroshyenko","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-3565(24)29291-0","article-title":"The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat","volume":"299","author":"Stanhope","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2011.09.017","article-title":"The M1\/M4 preferring agonist xanomeline is analgesic in rodent models of chronic inflammatory and neuropathic pain via central site of action","volume":"152","author":"Martino","year":"2011","journal-title":"Pain"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.2147\/tcrm.1.2.157.62912","article-title":"Trospium chloride: an update on a quaternary anticholinergic for treatment of urge urinary incontinence","volume":"1","author":"Guay","year":"2005","journal-title":"Ther Clin Risk Manag"},{"key":"B62","article-title":"Effects of trospium chloride on the lower urinary tract function","volume":"36","author":"Suzuki","year":"1990","journal-title":"Hinyokika Kiyo"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-011-0803-z","article-title":"Brain penetration of the OAB drug trospium chloride is not increased in aged mice","volume":"31","author":"Kranz","year":"2013","journal-title":"World J Urol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-023-06362-2","article-title":"Evidence of trospium's ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results","volume":"240","author":"Breier","year":"2023","journal-title":"Psychopharmacology"},{"key":"B65","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.schres.2025.12.015","article-title":"Long-term efficacy, safety, and tolerability of xanomeline and trospium chloride in schizophrenia: a 52-week open-label trial (EMERGENT-5)","volume":"288","author":"Kaul","year":"2026","journal-title":"Schizophr Res"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyaf045","article-title":"Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia: a systematic review, meta-analysis and Bayesian sensitivity analysis","volume":"29","author":"Sharma","year":"2026","journal-title":"Int J Neuropsychopharmacol."},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S503494","article-title":"Xanomeline and trospium chloride versus placebo for the treatment of schizophrenia: a post hoc analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed","volume":"21","author":"Citrome","year":"2025","journal-title":"Neuropsychiatr Dis Treat"},{"key":"B68","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41537-022-00320-1","article-title":"Safety and tolerability of KarXT (xanomeline\u2013trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia","volume":"8","author":"Correll","year":"2022","journal-title":"Schizophrenia"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ijnp\/pyaf045","article-title":"Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia: a systematic review, meta-analysis and Bayesian sensitivity analysis","volume":"29","author":"Sharma","year":"2025","journal-title":"Int J Neuropsychopharmacol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.21m14316","article-title":"Antipsychotic efficacy of KarXT (xanomeline-trospium): post hoc analysis of Positive and Negative Syndrome Scale categorical response rates, time course of response, and symptom domains of response in a phase 2 study","volume":"83","author":"Weiden","year":"2022","journal-title":"J Clin Psychiatry"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1093\/schizbullopen\/sgag003","article-title":"A qualitative investigation of the experience of taking xanomeline and trospium chloride for schizophrenia, Part 2: perceived changes in subjective quality of life and medication satisfaction","volume":"7","author":"Weiden","year":"2026","journal-title":"Schizophr Bull Open"},{"key":"B72","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jpsychires.2018.07.006","article-title":"The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: a critical and comprehensive review","volume":"108","author":"Girgis","year":"2019","journal-title":"J Psychiatr Res"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911772","article-title":"A non-D2 receptor binding drug for the treatment of schizophrenia","volume":"382","author":"Koblan","year":"2020","journal-title":"N Engl J Med"},{"key":"B74","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41537-021-00190-z","article-title":"Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month open-label extension study","volume":"7","author":"Correll","year":"2021","journal-title":"NPJ Schizophr"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial","volume":"383","author":"Cummings","year":"2014","journal-title":"Lancet"},{"key":"B76","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.biopsych.2016.11.014","article-title":"Bitopertin in negative symptoms of schizophrenia\u2014results from the phase III FlashLyte and DayLyte studies","volume":"82","author":"Bugarski-Kirola","year":"2017","journal-title":"Biol Psychiatry"},{"key":"B77","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S2215-0366(21)00386-2","article-title":"Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe","volume":"9","author":"Bugarski-Kirola","year":"2022","journal-title":"Lancet Psychiatry"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbaf034","article-title":"A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pimavanserin as an adjunctive treatment for the negative symptoms of schizophrenia (ADVANCE-2) in patients with predominant negative symptoms","volume":"52","author":"Bugarski-Kirola","year":"2026","journal-title":"Schizophr Bull"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2014.163","article-title":"Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study","volume":"71","author":"Umbricht","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318218dcd5","article-title":"A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia","volume":"31","author":"Kinon","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222413185","article-title":"Therapeutic potential of TAAR1 agonists in schizophrenia: evidence from preclinical models and clinical studies","volume":"22","author":"Dedic","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.1c00527","article-title":"Ulotaront: a TAAR1 agonist for the treatment of schizophrenia","volume":"13","author":"Heffernan","year":"2022","journal-title":"ACS Med Chem Lett"},{"key":"B83","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/ijnp\/pyad049","article-title":"In vitro comparison of ulotaront (SEP-363856) and ralmitaront (RO6889450): two TAAR1 agonist candidate antipsychotics","volume":"26","author":"\u00c5gren","year":"2023","journal-title":"Int J Neuropsychopharmacol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2026.1759454","article-title":"TAAR1-mediated pathways regulating nigrostriatal function and the discovery and pharmacological characterization of a novel TAAR1 agonist, Selutaront","volume":"17","author":"Zhang","year":"2026","journal-title":"Front Pharmacol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.2174\/0113895575435251251114091416","article-title":"Potential of small molecule TAAR-1 agonists for the therapy of neurodegenerative psychosis: a medicinal chemistry perspective","volume":"26","author":"Dash","year":"2026","journal-title":"Mini-Rev Med Chem"},{"key":"B86","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","article-title":"Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses","volume":"51","author":"Krystal","year":"1994","journal-title":"Arch Gen Psychiatry"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.148.10.1301","article-title":"Recent advances in the phencyclidine model of schizophrenia","volume":"148","author":"Javitt","year":"1991","journal-title":"Am J Psychiatry"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1007\/s10571-006-9062-8","article-title":"Glutamate and schizophrenia: beyond the dopamine hypothesis","volume":"26","author":"Coyle","year":"2006","journal-title":"Cell Mol Neurobiol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbs076","article-title":"NMDA receptor and schizophrenia: a brief history","volume":"38","author":"Coyle","year":"2012","journal-title":"Schizophr Bull"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2004.12.037","article-title":"D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia","volume":"57","author":"Heresco-Levy","year":"2005","journal-title":"Biol Psychiatry"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.62.11.1196","article-title":"Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study","volume":"62","author":"Lane","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2007.06081358","article-title":"The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments","volume":"164","author":"Buchanan","year":"2007","journal-title":"Am J Psychiatry"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.2174\/138161210790883615","article-title":"Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia: a critical review and meta-analysis","volume":"16","author":"Tsai","year":"2010","journal-title":"Curr Pharm Des"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/nm1632","article-title":"Activation of mGlu2\/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial","volume":"13","author":"Patil","year":"2007","journal-title":"Nat Med"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2021.11.032","article-title":"New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics","volume":"132","author":"Lobo","year":"2022","journal-title":"Neurosci Biobehav Rev"},{"key":"B96","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.coph.2011.02.007","article-title":"The role of serotonin receptors in the action of atypical antipsychotic drugs","volume":"11","author":"Meltzer","year":"2011","journal-title":"Curr Opin Pharmacol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2016.1174577","article-title":"ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes","volume":"16","author":"Davis","year":"2016","journal-title":"Expert Rev Neurother"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252413289","article-title":"Exploring the pharmacological and clinical features of lumateperone: a promising novel antipsychotic","volume":"25","author":"Sowa-Ku\u0107ma","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.108.140350","article-title":"Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats","volume":"327","author":"Brady","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0800567105","article-title":"Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia","volume":"105","author":"Chan","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2014.2","article-title":"Antipsychotic drug-like effects of the selective M4 muscarinic acetylcholine receptor positive allosteric modulator VU0152100","volume":"39","author":"Byun","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01990-0","article-title":"Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial","volume":"400","author":"Krystal","year":"2022","journal-title":"Lancet"},{"key":"B103","unstructured":"AbbVie provides update on phase 2 results for emraclidine in schizophrenia\n          \n          \n          North Chicago, IL\n          AbbVie\n          \n          2024"},{"key":"B104","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.neubiorev.2015.05.011","article-title":"The muscarinic system, cognition and schizophrenia","volume":"55","author":"Carruthers","year":"2015","journal-title":"Neurosci Biobehav Rev"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-020-00916-0","article-title":"The M1\/M4 preferring muscarinic agonist xanomeline modulates functional connectivity and NMDAR antagonist induced changes in the mouse brain","volume":"46","author":"Montani","year":"2021","journal-title":"Neuropsychopharmacology"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/s44220-025-00529-w","article-title":"Preliminary real-world predictors of response to muscarinic targeting in psychosis","volume":"3","author":"Halassa","year":"2025","journal-title":"Nat Ment Health"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1828831\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:42:09Z","timestamp":1790163729000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1828831\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":106,"alternative-id":["10.3389\/fpsyt.2026.1828831"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1828831","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"article-number":"1828831"}}